Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 124 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Carbidopa Levodopa Clear all
Suspended Phase 2Phase 3 Interventional

Effects of 5HTP and LDOPA on CNS Excitability After SCI

NCT04000919
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
5HTP, L-DOPA, Placebo oral tablet, Carbidopa
Drug
Lead sponsor
Jessica M D'Amico
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 17, 2022 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

High and Low Dose Carbidopa Treatment of Parkinson's Disease

NCT01399905
View directory record Official record
Conditions
Parkinson's Disease
Interventions
carbidopa
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
35 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 9, 2020 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's Disease

NCT05094050
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2023 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 3 Interventional

A Study of Istradefylline (KW-6002) in Treating Patients With Parkinson's Disease on Levodopa

NCT00199420
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Istradefylline (KW-6002)
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
30 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 25, 2024 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).

NCT00974974
View directory record Official record
Conditions
Parkinson's Disease
Interventions
IPX066, IR CD-LD
Drug
Lead sponsor
Impax Laboratories, LLC
Industry
Eligibility
30 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease

NCT00335153
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Levodopa-carbidopa intestinal gel, CADD-Legacy® 1400 ambulatory infusion pump, PEG tube, J-tube
Drug · Device
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
30 Years and older
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2015 · Synced Oct 17, 2026, 4:35 AM EDT
Recruiting Phase 4 Interventional

Personalized Real-Time DBS and PD Mechanisms

NCT06013956
View directory record Official record
Conditions
Parkinson Disease
Interventions
Neurostimulation, Carbidopa 25/Levodopa 100Mg Tab
Device · Drug
Lead sponsor
David Escobar
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Levodopa for Diabetic Retinopathy

NCT07444892
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Levodopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 3 Interventional

Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

NCT04750226
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 17, 2026, 4:35 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Improving Therapeutic Learning for PTSD

NCT04558112
View directory record Official record
Conditions
PTSD, Post Traumatic Stress Disorder
Interventions
L-DOPA, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 50 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Austin, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Neurobiological Principles Applied to the Rehabilitation of Stroke Patients

NCT00715520
View directory record Official record
Conditions
Stroke
Interventions
Transcranial Magnetic Stimulation (TMS), Carbidopa-Levodopa, Methylphenidate, Amphetamine Sulfate, Placebo, Sham Transcranial Magnetic Stimulation (TMS), Transcranial Magnetic Stimulation (TMS) Training
Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 3 Interventional

Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease

NCT04379050
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
ABBV-951
Drug
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Sun City, Arizona • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 3 Interventional Results available

A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)

NCT02549092
View directory record Official record
Conditions
Advanced Parkinson's Disease
Interventions
Optimized Medical Treatment, Levodopa-Carbidopa Intestinal Gel, Nasojejunal (NJ) tube, Percutaneous endoscopic gastrostomy with a jejunal (PEG-J) tube
Drug · Device
Lead sponsor
AbbVie
Industry
Eligibility
30 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
8
States / cities
Fountain Valley, California • Boca Raton, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 2 Interventional Results available

Extension, Carbidopa-levodopa in Neovascular Age-related Macular Degeneration (AMD)

NCT03197493
View directory record Official record
Conditions
Macula; Degeneration, Retina
Interventions
carbidopa-levodopa 25-100 mg
Drug
Lead sponsor
Snyder, Robert W., M.D., Ph.D., P.C.
Individual
Eligibility
50 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Inflammation-related Alterations in Neurocircuitry: Reversal With Levodopa

NCT02513485
View directory record Official record
Conditions
Depression
Interventions
Levodopa+carbidopa, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2022 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dopaminergic Enhancement of Rehabilitation Therapy Early After Stroke

NCT05369533
View directory record Official record
Conditions
Stroke
Interventions
Telerehabilitation, Sinemet Pill, Placebo
Device · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 17, 2026, 4:35 AM EDT
Active, not recruiting Phase 3 Interventional

Infusion of Apomorphine: Long-term Safety Study

NCT02339064
View directory record Official record
Conditions
Idiopathic Parkinson's Disease
Interventions
apomorphine infusion
Drug
Lead sponsor
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 4 Interventional Results available

Effect of L-dopa In Subacute Back Pain Population

NCT01951105
View directory record Official record
Conditions
Sub-acute Back Pain
Interventions
Naproxen, Carbidopa/Levodopa, Placebo
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Oct 17, 2026, 4:35 AM EDT
Active, not recruiting Phase 2 Interventional

Project 1 Aim 2, Adaptations of the Brain in Chronic Pain With Opioid Exposure

NCT05463367
View directory record Official record
Conditions
Opioid Use, Opioid Dependence, Opioid-use Disorder, Narcotic Use, Back Pain, Back Injuries, Chronic Pain, Chronic Low-back Pain, Pain, Chronic, Pain;Back Low;Chronic, Pain, Back
Interventions
Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet, Naproxen 500 Mg, Opioids
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 27, 2024 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Levodopa Following Administration of CVT 301 (Levodopa Inhalation Powder) in Adults With Asthma

NCT02633007
View directory record Official record
Conditions
Asthma
Interventions
CVT-301 (levodopa inhalation powder), Carbidopa, Placebo
Drug · Other
Lead sponsor
Acorda Therapeutics
Industry
Eligibility
25 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Daytona Beach, Florida • North Dartmouth, Massachusetts • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 13, 2016 · Synced Oct 17, 2026, 4:35 AM EDT
Not listed Phase 3 Interventional

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

NCT02615873
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years to 100 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 17, 2026, 4:35 AM EDT
Withdrawn Phase 2 Interventional

Use of Zolpidem in Parkinson's Disease

NCT01351168
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Levodopa, Zolpidem first dose, Zolpidem second dose, sugar pill
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
30 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 3, 2012 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Sustained Release Oral Formulation for Treatment of Parkinson's Disease

NCT05471609
View directory record Official record
Conditions
Healthy Volunteers
Interventions
levodopa/carbidopa oral formulation A, levodopa/carbidopa oral formulation B
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 17, 2026, 4:35 AM EDT
Completed Early Phase 1 Interventional

Short-term Effects of TOLCAPONE on Transthyretin Stability in Subjects With Leptomeningeal TTR Amyloidosis (ATTR)

NCT03591757
View directory record Official record
Conditions
Transthyretin Amyloidosis, Amyloidosis, Leptomeningeal, Transthyretin-Related
Interventions
Tolcapone
Drug
Lead sponsor
Boston University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 14, 2019 · Synced Oct 17, 2026, 4:35 AM EDT